

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
VB	AA1	5,200,320	04/06/1993	Sette et al.	-	-	12/07/1987
VB	AB1	5,503,829	04/02/1996	Ladant et al.	-	-	11/07/1994
VB	AC1	5,662,907	09/02/1997	Kubo et al.	-	-	01/25/1994
VB	AD1	6,034,214	03/07/2000	Boon et al.	-	-	12/13/1994
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
VB	AL1	EP 0 044 710 A1	01/27/1982	Europe	-	-	Yes No
VB	AM1	EP 0 226 513 A1	06/24/1987	Europe	-	-	Yes X No
VB	AN1	WO 92/02543 A1	02/20/1992	WIPO	-	-	Yes No
VB	AO1	WO 92/12996 A2	08/06/1992	WIPO	-	-	Yes No
VB	AP1	WO 92/21033 A1	11/26/1992	WIPO	-	-	Yes X No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

VB	AR	1	Aichele, P., et al., "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," J. Exp. Med. 171:1815-1820, Rockefeller University Press (1990)				
VB	AS	1	Alexander, J., et al., "Derivation of HLA-A11/K ^b Transgenic Mice. Functional CTL Repertoire and Recognition of Human A11-Restricted CTL Epitopes," J. Immunol. 159:4753-4761, The American Association of Immunologists (November 1997)				
VB	AT	1	Bergmann, C.C., et al., "Differential Effects of Flanking Residues on Presentation of Epitopes from Chimeric Peptides," J. Virol. 68:5306-5310, American Society for Microbiology (August 1994)				

EXAMINER	DATE CONSIDERED 5/9/2000
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 2060.0130000/HCC/PAC		APPLICATION NO. 09/458,298	
				APPLICANT FIKES et al.			
				FILING DATE December 10, 1999		GROUP 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
M31	AL2	WO 93/03764 A1	03/04/1993	WIPO	—	—	Yes No
M31	AM2	WO 94/03205 A1	02/17/1994	WIPO	—	—	Yes No
M21	AN2	WO 94/11738 A1	05/26/1994	WIPO	—	—	Yes X No
M31	AO2	WO 94/20127 A1	09/15/1994	WIPO	—	—	Yes No
M1	AP2	WO 96/03140 A1	02/08/1996	WIPO	—	—	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
M31	AR	2	Bertoni, R., et al., "Human Histocompatibility Leukocyte Antigen-binding Supermotifs Predict Broadly Cross-reactive Cytotoxic T Lymphocyte Responses in Patients with Acute Hepatitis," <i>J. Clin. Invest.</i> 100:503-513, The American Society for Clinical Investigation, Inc. (August 1997)
↓	AS	2	Bertoni, R., et al., "Human Class I Supertypes and CTL Repertoires Extend to Chimpanzees," <i>J. Immunol.</i> 161:4447-4455, American Association of Immunologists (October 1998)
↓	AT	2	Bjorkman, P.J., et al., "Structure of the human class I histocompatibility antigen, HLA-A2," <i>Nature</i> 329:506-512, Macmillan Publishers, Ltd. (1987)

EXAMINER	DATE CONSIDERED 5/4/2004
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.0130000/HCC/PACAPPLICATION NO.
09/458,298APPLICANT
FIKES et al.FILING DATE
December 10, 1999GROUP
1644


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	3	Bjorkman, P.J., et al., "The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens," <i>Nature</i> 329:512-518, Macmillan Publishers, Ltd. (1987)
	AS	3	Buus, S., et al., "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia," <i>Science</i> 242:1045-1047, American Association for the Advancement of Science (1988)
	AT	3	Carreno, B.M., et al., "HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides," <i>Proc. Natl. Acad. Sci. USA</i> 87:3420-3424, National Academy Press (1990)

EXAMINER

DATE CONSIDERED




4/5/2005


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 2060.0130000/HCC/PAC		APPLICATION NO. 09/458,298	
		APPLICANT FIKES et al.			
		FILING DATE December 10, 1999		GROUP 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	4	Corr, M., et al., "Endogenous Peptides of a Soluble Major Histocompatibility Complex Class I Molecule, H-2L ^d : Sequence Motif, Quantitative Binding, and Molecular Modeling of the Complex," J. Exp. Med. 176:1681-1692, Rockefeller University Press (December 1992)
	AS	4	De Bruijn, M.L.H., et al., "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," Eur. J. Immunol. 21:2963-2970, VCH Verlagsgesellschaft mbH (1991)
	AT	4	Del Val, M., et al., "Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein," Cell 66:1145-1153, Cell Press (1991)

EXAMINER 	DATE CONSIDERED 5/4/2004
--	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 2060.0130000/HCC/PAC		APPLICATION NO. 09/458,298	
		APPLICANT FIKES et al.			
		FILING DATE December 10, 1999		GROUP 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	5	Deres, K., et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <i>Nature</i> 342:561-564, Macmillan Publishers, Ltd. (1989)
	AS	5	DiBrino, M., et al., "HLA-A1 and HLA-A3 T Cell Epitopes Derived from Influenza Virus Proteins Predicted from Peptide Binding Motifs," <i>J. Immunol.</i> 151:5930-5935, The Association of Immunologists (December 1993)
	AT	5	DiBrino, M., et al., "Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides," <i>Proc. Natl. Acad. Sci. USA</i> 90:1508-1512, National Academy Press (February 1993)

EXAMINER	DATE CONSIDERED 5/4/2007
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.0130000/HCC/PACAPPLICATION NO.
09/458,298APPLICANT
FIKES et al.FILING DATE
December 10, 1999GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

BS	AR	6	Ding, Y.-H., et al., "Two Human T Cell Receptors Bind in a Similar Diagonal Mode to the HLA-A2/Tax Peptide Complex Using Different TCR Amino Acids," <i>Immunity</i> 8:403-11, Cell Press (April 1998)
I	AS	6	Eisenlohr, L.C., et al., "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> 175:481-487, The Rockefeller University Press (February 1992)
J	AT	6	Engelhard, V.H., "Structure of peptides associated with MHC Class I molecules," <i>Curr. Opin. Immunol.</i> 6:13-23, Current Biology, Ltd. (February 1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 2060.0130000/HCC/PAC		APPLICATION NO. 09/458,298	
			APPLICANT FIKES et al.			
			FILING DATE December 10, 1999		GROUP 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
B35	AR	7	Falk, K., et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," <i>Nature</i> 351:290-296, Macmillan Publishers, Ltd. (1991)
↓	AS	7	Falk, K., et al., "MHC peptide motif register. Peptide motifs of HLA-B35 and -B37 molecules," <i>Immunogenetics</i> 38:161-162, Springer-Verlag (April 1993)
↓	AT	7	Falk, K., et al., "Allele-specific peptide ligand motifs of HLA-C molecules," <i>Proc. Natl. Acad. Sci. USA</i> 90:12005-12009, National Academy Press (December 1993)

EXAMINER	DATE CONSIDERED 5/14/2004
----------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

B _s	AR	8	Falk, K., et al., "Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules," <i>Immunogenetics</i> 39:230-242, Springer-Verlag (February 1994)
↓	AS	8	Falk, K., et al., "Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules," <i>Immunogenetics</i> 40:238-241, Springer-Verlag (July 1994)
↓	AT	8	Foon, K.A., "Biological Response Modifiers: The New Immunotherapy," <i>Cancer Res.</i> 49:1621-1639, American Association for Cancer Research (1989)

EXAMINER	DATE CONSIDERED 5/4/2004
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Geysen, H.M., et al., "Cognitive Features of Continuous Antigenic Determinants," J. Mol. Recognit. 1:32-41, Heyden & Sons, Ltd. (1988)
	AS	2	Guo, H.-C., et al., "Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle," Nature 360:364-366, Macmillan Publishers, Ltd. (November 1992)
	AT	2	Henderson, R.A., et al., "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation," Science 255:1264-1266, American Association for the Advancement of Science (March 1992)

EXAMINER 	DATE CONSIDERED 5/4/2009
--	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.0130000/HCC/PACAPPLICATION NO.
09/458,298APPLICANT
FIKES et al.FILING DATE
December 10, 1999GROUP
1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Hill, A., et al., "Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7," <i>Eur. J. Immunol.</i> 25:18-24, VCH Verlagsgesellschaft mbH (January 1995)
	AS	<u>10</u>	Hunt, D.F., et al., "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 255:1261-1263, American Association for the Advancement of Science (March 1992)
	AT	<u>10</u>	Ishioka, G.Y., et al., "Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes," <i>J. Immunol.</i> 162:3915-3925, The American Association of Immunologists (April 1999)

EXAMINER

DATE CONSIDERED

5/4/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 2060.0130000/HCC/PAC

APPLICATION NO.
 09/458,298

APPLICANT
 FIKES et al.

FILING DATE
 December 10, 1999

GROUP
 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

P31	AR	<u>11</u>	Jameson, S.C., and Bevan, M.J., "Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a K ^B -restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs," <i>Eur. J. Immunol.</i> 22:2663-2667, VCH Verlagsgesellschaft mbH (October 1992)
↓	AS	<u>11</u>	Jardetzky, T.S., et al., "Identification of self peptides bound to purified HLA-B27," <i>Nature</i> 353:326-329, Macmillan Publishers, Ltd. (1991)
↓	AT	<u>11</u>	Kannagi, M., et al., "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cells," <i>J. Virol.</i> 66:2928-2933, American Society for Microbiology (May 1992)

EXAMINER

R L

DATE CONSIDERED

5/4/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 2060.0130000/HCC/PAC

APPLICATION NO.
 09/458,298

APPLICANT
 FIKES et al.

FILING DATE
 December 10, 1999

GROUP
 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Kast, W.M., et al., "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 88:2283-2287, National Academy Press (1991)
	AS	<u>12</u>	Kast, W.M., et al., "Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination," <i>Eur. J. Immunol.</i> 23:1189-1192, VCH Verlagsgesellschaft mbH (May 1993)
	AT	<u>12</u>	Krieger, J.I., et al., "Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition," <i>J. Immunol.</i> 146:2331-2340, American Association of Immunologists (1991)

EXAMINER

DATE CONSIDERED

5/4/2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.0130000/HCC/PACAPPLICATION NO.
09/458,298APPLICANT
FIKES et al.FILING DATE
December 10, 1999GROUP
1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	13	Lipford, G.B., et al., "Primary in Vivo Responses to Ovalbumin. Probing the Predictive Value of the K ^b Binding Motif," <i>J. Immunol.</i> 150:1212-1222, The American Association of Immunologists (February 1993)
	AS	13	Maryanski, J.L., et al., "Synthetic peptides as antigens and competitors in recognition by H-2-restricted cytolytic T cells specific for HLA," <i>J. Exp. Med.</i> 167:1391-1405, Rockefeller University Press (1988)
	AT	13	Maryanski, J.L., et al., "Competitor Analogs for Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers," <i>Cell</i> 60:63-72, Cell Press (1990)

EXAMINER

DATE CONSIDERED

5/4/2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.0130000/HCC/PACAPPLICATION NO.
09/458,298APPLICANT
FIKES et al.FILING DATE
December 10, 1999GROUP
1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>14</u>	Morrison, J., et al., "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 22:903-907, VCH Verlagsgesellschaft mbH (April 1992)
	AS	<u>14</u>	Niedermann, G., et al., "The proteolytic fragments generated by vertebrate proteosomes: Structural relationships to major histocompatibility complex class I binding peptides," <i>Proc. Natl. Acad. Sci. USA</i> 93:8572-8577, National Academy Press (August 1996)
	AT	<u>14</u>	Ochoa-Garay, J., et al., "The ability of peptides to induce cytotoxic T cells in vitro does not strongly correlate with their affinity for the H-2L ^d molecule: implications for vaccine design and immunotherapy," <i>Mol. Immunol.</i> 34:273-281, Elsevier Science, Ltd. (February 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.0130000/HCC/PACAPPLICATION NO.
09/458,298APPLICANT
FIKES et al.FILING DATE
December 10, 1999GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

B31	AR	15	Pamer, E.G., et al., "Precise prediction of a dominant class I MHC-restricted epitome of <i>Listeria monocytogenes</i> ," <i>Nature</i> 353:852-855, Macmillan Publishers, Ltd. (1991)
f	AS	15	Parham, P., et al., "The Origins of HLA-A,B,C Polymorphism," <i>Immunol. Rev.</i> 143:141-180, Munksgaard (February 1995)
2	AT	15	Parker, K.C., et al., "Peptide Binding to HLA-A2 and HLA-B27 Isolated from <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 267:5451-5459, American Society for Biochemistry and Molecular Biology, Inc. (March 1992)

EXAMINER

DATE CONSIDERED

5/4/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.0130000/HCC/PACAPPLICATION NO.
09/458,298APPLICANT
FIKES et al.FILING DATE
December 10, 1999GROUP
1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Parker, K.C., et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2," <i>J. Immunol.</i> 149:3580-3587, American Association of Immunologists (December 1992)
	AS	<u>16</u>	Rammensee, H.-G., et al., "Peptides Naturally Presented by MHC Class I Molecules," <i>Annu. Rev. Immunol.</i> 11:213-244, Annual Reviews, Inc. (January 1993)
	AT	<u>16</u>	Rammensee, H.-G., et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 41:178-228, Springer-Verlag (February 1995)

EXAMINER

DATE CONSIDERED

5/4/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>17</u>	Reddehase, M.J., et al., "A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes," Nature 337:651-653, Macmillan Publishers, Ltd. (1989)
	AS	<u>17</u>	Romero, P., et al., "H-2K ^d -restricted Antigenic Peptides Share a Simple Binding Motif," J. Exp. Med. 174:603-612, Rockefeller University Press (1991)
	AT	<u>17</u>	Rothbard, J.B., "Major histocompatibility complex-peptide interactions," Curr. Opin. Immunol. 2:99-105, Current Biology, Ltd. (1989)

EXAMINER 	DATE CONSIDERED <u>5/4/2004</u>
--	---------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>18</u>	Röttschke, O., et al., "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," Nature 348:252-254, Macmillan Publishers, Ltd. (1990)
	AS	<u>18</u>	Röttschke, O., et al., "Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y," Science 249:283-287, American Association for the Advancement of Science (1990)
	AT	<u>18</u>	Röttschke, O., and Falk, K., "Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway," Immunol. Today 12:447-455, Elsevier Science Publishers, Ltd. (1991)

EXAMINER	DATE CONSIDERED 5/4/2001
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	19	Rotzschke, O., et al., "Peptide motifs of closely related HLA class I molecules encompass substantial differences," <i>Eur. J. Immunol.</i> 22:2453-2456, VCH Verlagsgesellschaft mbH (September 1992)
	AS	19	Röttschke, O., and Falk, K., "Origin, structure and motifs of naturally processed MHC class II ligands," <i>Curr. Opin. Immunol.</i> 6:45-51, Current Biology, Ltd. (February 1994)
	AT	19	Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in <i>Peptide Hormones</i> , Parsons, J.A., ed., University Park Press, Baltimore, MD, pp.1-7 (1976)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 2060.0130000/HCC/PAC		APPLICATION NO. 09/458,298	
				APPLICANT FIKES et al.			
				FILING DATE December 10, 1999		GROUP 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	20	Ruppert, J., et al., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," Cell 74:929-937, Cell Press (September 1993)
	AS	20	Schulz, M., et al., "Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide," Eur. J. Immunol. 21:1181-1185, VCH Verlagsgesellschaft mbH (1991)
	AT	20	Sette, A., et al., "Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis," Proc. Natl. Acad. Sci. USA 86:3296-3300, National Academy Press (1989)

EXAMINER	DATE CONSIDERED 5/4/2004
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644




U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>21</u>	Sette, A., et al., "Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules," <i>J. Immunol.</i> 147:3893-3900, The American Association of Immunologists (1991)
	AS	<u>21</u>	Sette, A., et al., "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> 153:5586-5592, The American Association of Immunologists (December 1994)
	AT	<u>21</u>	Shastri, N., et al., "Presentation of Endogenous Peptide/MHC Class I Complexes Is Profoundly Influenced by Specific C-Terminal Flanking Residues," <i>J. Immunol.</i> 155: 4339-4346, The American Association of Immunologists (November 1995)

EXAMINER 	DATE CONSIDERED 5/4/2001
--	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>22</u>	Sherman, L.A., et al., "Extracellular Processing of Peptide Antigens That Bind Class I Major Histocompatibility Molecules," <i>J. Exp. Med.</i> 175:1221-1226, The Rockefeller University Press (May 1992)
	AS	<u>22</u>	Shimojo, N., et al., "Specificity of peptide binding by the HLA-A2.1 molecule," <i>J. Immunol.</i> 143:2939-2947, The American Association of Immunologists (1989)
	AT	<u>22</u>	Sidney, J., et al., "Several HLA Alleles Share Overlapping Peptide Specificities," <i>J. Immunol.</i> 154:247-259, The American Association of Immunologists (January 1995)




EXAMINER	DATE CONSIDERED 5/4/2004
----------	--------------------------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	23	Threlkeld, S.C., et al., "Degenerate and Promiscuous Recognition by CTL of Peptides Presented by the MHC Class I A3-like Superfamily. Implications for Vaccine Development," J. Immunol. 159:1648-1657, The American Association of Immunologists (August 1997)				
	AS	23	Wentworth, P.A., et al., "Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice," Eur. J. Immunol. 26:97-101, VCH Verlagsgesellschaft mbH (January 1996)				
	AT	23	Whitton, J.L., et al., "Molecular Analyses of a Five-Amino-Acid Cytotoxic T-Lymphocyte (CTL) Epitope: an Immunodominant Region Which Induces Nonreciprocal CTL Cross-Reactivity," J. Virol. 63:4303-4310, American Society for Microbiology (1989)				

EXAMINER		DATE CONSIDERED 5/7/2001
----------	---	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	2060.0130000/HCC/PAC	09/458,298
	APPLICANT	
	FIKES et al.	
	FILING DATE	GROUP
	December 10, 1999	1644

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Ph	AR	24	Yewdell, J.W., and Bennink, J.R., "Cell Biology of Antigen Processing and Presentation to Major Histocompatibility Complex Class I Molecule-Restricted T Lymphocytes," <i>Adv. Immunol.</i> 52:1-123, Academic Press (July 1992)
I	AS	24	York, I.A., and Rock, K.L., "Antigen processing and presentation by the class I major histocompatibility complex," <i>Annu. Rev. Immunol.</i> 14:369-396, Annual Reviews, Inc. (April 1996)
↓	AT	24	Zhang, Q-J., et al., "An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins," <i>Proc. Natl. Acad. Sci. USA</i> 90:2217-2221, National Academy Press (March 1993)

EXAMINER	DATE CONSIDERED
	5/4/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 2060.0130000/HCC/PAC

APPLICATION NO.
 09/458,298

APPLICANT
 FIKES et al.

FILING DATE
 December 10, 1999

GROUP
 1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	25	Parker, K.C., et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," J. Immunol. 152:163-175, The American Association of Immunologists (January 1994)
	AS	25	Dialog File 351, Accession No. 7180926, Derwent WPI English language abstract for EP 0 226 513.
	AT	25	Dialog File 351, Accession No. 9263567, Derwent WPI English language abstract for WO 92/21033.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 2060.0130000/HCC/PAC		APPLICATION NO. 09/458,298	
				APPLICANT FIKES et al.			
				FILING DATE December 10, 1999		GROUP 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	26	Dialog File 351, Accession No. 9888606, Derwent WPI English language abstract for WO 94/11738.
AS			
AT			

EXAMINER	DATE CONSIDERED 5/4/2004
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
MS	AE1	5,342,774	08/30/1994	Boon et al.	-	-	12/12/1991
	AF1	5,405,940	04/11/1995	Boon et al.	-	-	08/31/1992
	AG1	5,462,871	10/31/1995	Boon-Falleur et al.	-	-	06/07/1993
	AH1	5,695,994	12/09/1997	Boon-Falleur et al.	-	-	05/17/1995
	AI1	5,750,395	05/12/1998	Fikes et al.	-	-	06/05/1995
	AJ1	5,965,381	10/12/1999	van der Bruggen et al.	-	-	03/06/1998
	AK1	5,965,535	10/12/1999	Chaux et al.	-	-	09/12/1997

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
MS	AL3	WO 94/05304 A1	03/17/1994	WIPO	-	-	Yes No
MS	AM3	WO 95/04542 A1	02/16/1995	WIPO	-	-	Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
MS	AS	26	Boel, P., et al., "BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes," <i>Immunity</i> 2:167-175, Cell Press (February 1995)
MS	AT	26	Boon, T., "Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy," <i>Int. J. Cancer</i> 54:177-180, Wiley-Liss, Inc. (May 1993)

EXAMINER	DATE CONSIDERED 5/4/2007
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
M/S	AA2	6,037,135	03/14/2000	Kubo et al.	7	—	11/29/1993
↓	AB2	2002/0168374 A1	11/14/2002	Kubo et al.	—	—	03/20/1997
↓	AC2	2002/0177694 A1	11/28/2002	Sette et al.	—	—	02/03/1998
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

✓ M/S	AR	27	Celis, E., et al., "Identification of potential CTL epitopes of tumor-associated antigen Mage-1 for five common HLA-A alleles," <i>Mol. Immunol.</i> 31:1423-1430, Elsevier Science, Ltd. (December 1994)
↓	AS	27	Celis, E., et al., "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 91:2105-2109, National Academy Press (March 1994)
↓	AT	27	Cotran, R.S., et al., "Neoplasia," in <i>Robbins Pathologic Basis of Disease</i> , 4 th ed., W.B. Saunders Staff, ed., W.B. Saunders Company, Philadelphia, PA, pp. 296-299 (1989)

EXAMINER	DATE CONSIDERED 5/09/2004
----------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
MS	AR	28	Ding, M., et al., "Cloning and Analysis of MAGE-1-Related Genes," <i>Biochem. Biophys. Res. Commun.</i> 202:549-555, Academic Press (July 1994)
I	AS	28	Gaugler, B., et al., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes," <i>J. Exp. Med.</i> 179:921-930, The Rockefeller University Press (March 1994)
A	AT	28	Hayashi, H., et al., "Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection," <i>J. Immunol.</i> 149:1223-1229, The American Association of Immunologists (August 1992)

EXAMINER	DATE CONSIDERED 5/4/2001
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MS	AR	29	Kawakami, Y., et al., "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression," <i>J. Immunol.</i> 154:3961-3968, The American Association of Immunologists (April 1995)
↓	AS	29	Kawashima, I., et al., "The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors," <i>Hum. Immunol.</i> 59:1-14, Elsevier Science, Inc. (January 1998)
↓	AT	29	Knuth, A., et al., "Cellular and humoral immune responses against cancer: implications for cancer vaccines," <i>Curr. Opin. Immunol.</i> 3:659-664, Current Biology, Ltd. (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 2060.0130000/HCC/PAC		APPLICATION NO. 09/458,298	
				APPLICANT FIKES et al.			
				FILING DATE December 10, 1999		GROUP 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
1231	AR	30	Oaks, M.K., et al., "Molecular Cytogenic Mapping of the Human Melanoma Antigen (MAGE) Gene Family to Chromosome Region Xq27-qter: Implications for MAGE Immunotherapy," Cancer Res. 54:1627-1629, American Association for Cancer Research (April 1994)
1	AS	30	Rivoltini, L., et al., "Induction of Tumor-Reactive CTL from Peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1," J. Immunol. 154:2257-2265, The American Association of Immunologists (March 1995)
2	AT	30	Salgaller, M.L., et al., "Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide," Cancer Immunol. Immunother. 39:105-116, Springer-Verlag (August 1994)

EXAMINER 	DATE CONSIDERED 5/4/00
--	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>31</u>	Slinguff, Jr., C.L., et al., "Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes Is Mediated by at Least Six Shared Peptide Epitopes," <i>J. Immunol.</i> 150:2955-2963, The American Association of Immunologists (April 1993)
	AS	<u>31</u>	Storkus, W.J., et al., "Identification of Human Melanoma Peptides Recognized by Class I Restricted Tumor Infiltrating T Lymphocytes," <i>J. Immunol.</i> 151:3719-3727, The American Association of Immunologists (October 1993)
	AT	<u>31</u>	Toes, R.E.M., et al., "Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells," <i>J. Immunol.</i> 160:4449-4456, The American Association of Immunologists (May 1998)

EXAMINER 	DATE CONSIDERED 5/4/2004
--	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644




U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>32</u>	Traversari, C., et al., "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E," <i>J. Exp. Med.</i> 176:1453-1457, The Rockefeller University Press (November 1992)
	AS	<u>32</u>	Tsai, V., et al., "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells," <i>J. Immunol.</i> 158:1796-1802, American Association of Immunologists (February 1997)
	AT	<u>32</u>	van der Bruggen, P., et al., "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," <i>Science</i> 254:1643-1647, American Association for the Advancement of Science (1991)

EXAMINER 	DATE CONSIDERED 5/4/2004
--	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 2060.0130000/HCC/PAC

APPLICATION NO.
 09/458,298

APPLICANT
 FIKES et al.

FILING DATE
 December 10, 1999

GROUP
 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Pr 3	AR	33	Viret, C., et al., "Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes," <i>Eur. J. Immunol.</i> 23:141-146, VCH Verlagsgesellschaft mbH (January 1993)
I	AS	33	Weynants, P., et al., "Expression of MAGE genes by non-small-cell lung carcinomas," <i>Int. J. Cancer</i> 56:826-829, Wiley-Liss, Inc. (March 1994)
A	AT	33	Zakut, R., et al., "Differential Expression of MAGE-1, -2, and -3 Messenger RNA in Transformed and Normal Human Cell Lines," <i>Cancer Res.</i> 53:5-8, American Association for Cancer Research (January 1993)

EXAMINER

DATE CONSIDERED

5/4/2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
<i>MB1</i>	AR	34	Copy of co-pending U.S. application 08/205,713, inventor Grey, filed March 4, 1994 (NOT PUBLISHED)
<i>MB1</i>	AS	34	Copy of co-pending U.S. application 08/344,824, inventors Sette et al., filed November 23, 1994 (NOT PUBLISHED)
<i>MB1</i>	AT	34	Copy of co-pending U.S. application 08/347,610, inventors Kubo et al., filed December 1, 1994 (NOT PUBLISHED)

EXAMINER <i>W L</i>	DATE CONSIDERED <i>5/4/2004</i>
---------------------	---------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0130000/HCC/PAC	APPLICATION NO. 09/458,298
	APPLICANT FIKES et al.	
	FILING DATE December 10, 1999	GROUP 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
M31	AR	35	Copy of co-pending U.S. application 08/452,843, inventors Sette et al., filed March 30, 1995 (NOT PUBLISHED).				
M31	AS	35	Copy of co-pending U.S. application 09/017,524, inventors Kubo et al., filed February 3, 1998 (NOT PUBLISHED).				
	AT	35	Copy of co-pending U.S. application 10/149,135, inventors Fikes et al., § 371 date February 19, 2003.				

EXAMINER 	DATE CONSIDERED 5/4/2004
--	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.